文献速递中医妇科中药与中成药合理使用中医内科

二仙汤治疗更年期综合征:一项更新的系统评价

Erxian decoction, a Chinese herbal formula, for menopausal syndrome: An updated systematic review.
PubMed 文献 · J Ethnopharmacol · 2019-01-15

部分研究显示二仙汤单用或联用可改善总有效率、中医证候评分及抑郁焦虑量表评分,但部分结局结果矛盾,证据质量中等至高,仍需严格随机对照试验。

要点

  • 二仙汤单用或联合激素可提高总有效率,并改善中医证候及抑郁焦虑评分。
  • 与激素比较,二仙汤在Kupperman指数及血清学指标上结果不一致。
  • 纳入研究质量偏低,主要结局证据质量为中等至高,结论需谨慎解读。

核心结论

  • 现有证据因纳入低质量研究且不可重复而无法做出确切评估,但二仙汤治疗更年期综合征值得进一步研究。
  • 未来仍需严格的随机对照试验验证二仙汤的疗效与安全性。

研究设计与样本

  • 更新版系统评价与Meta分析,电子检索8个数据库至2018年7月。
  • 纳入Cochrane Back Review Group偏倚风险评分≥7的随机对照试验。
  • 治疗组为二仙汤单用或辅助治疗,对照包括安慰剂、激素替代疗法、激素联合非激素药物、非激素药物及不治疗。

主要发现

  • 5项研究比较二仙汤与激素对Kupperman指数的效果,结果相互矛盾。
  • 1项研究显示二仙汤较安慰剂显著改善潮热总分、MRS总分及MENQOL总分(P<0.05)。
  • 10项二仙汤单用或2项辅助治疗研究的Meta分析显示,与激素相比可显著提高总有效率(P<0.05)。
  • 3项研究显示二仙汤加激素较单用激素显著降低中医证候评分、HAMD、SDS及SAS评分(P<0.05)。
  • 1项研究显示二仙汤较激素显著降低AIS评分(P<0.05);7项研究在改善血清学指标上结果矛盾。

关键数值与推荐

  • 主要结局指标为Kupperman指数、潮热总分、绝经评定量表(MRS)总分及绝经期特异性生活质量(MENQOL)总分。
  • 次要结局包括总临床有效率、中医证候评分、HAMD、SDS、SAS、AIS评分、血清学指标、血压及不良事件。
  • 纳入研究需符合更年期综合征既定诊断标准,且偏倚风险评分≥7。

临床怎么用

  • 二仙汤可作为更年期综合征改善总有效率及中医证候的辅助选择,但需结合激素治疗等方案个体化决策。
  • 对伴有抑郁、焦虑或失眠症状者,二仙汤联合激素可能有助于改善相关量表评分。
  • 应用时应关注不良反应报告,并知晓现有证据在主要结局上存在矛盾且质量有限。

局限性

  • 纳入研究质量偏低且不可重复,导致无法对证据做出确切评估。
  • 部分结局结果相互矛盾,血清学指标及Kupperman指数的效应尚不明确。
  • 多数研究未报告不良反应,安全性信息不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Erxian decoction (EXD), a famous Chinese herbal prescription, consists of Rhizoma Curculiginis, Herba Epimedii, Radix Morindae Officinalis, Radix Angelicae Sinensis, Cortex Phellodendri, Rhizoma Anemarrhenae, all of which are recorded in the Chinese Pharmacopoeia. OBJECTIVE: To conduct an updated systematic and meta-analysis investigating efficacy and safety of EXD for menopausal syndrome. METHODS: An electronic search was conducted in eight databases from inception until July 2018. Randomized controlled trials with risk-of-bias score ≥ 7 according to the Cochrane Back Review Group were included for analyses. All participants with a diagnosis of menopausal syndrome met the established criteria. The treatment group was EXD monotherapy or adjunct therapy. Comparators were placebo, hormone replace therapy, hormone plus nonhormonal agents, nonhormonal agents and no treatment. The primary outcome measurements were the Kupperman index, total hot flush scores, total menopause rating scale (MRS) scores and total menopause-specific quality of life (MENQOL) scores. The secondary outcomes were total clinical effective rate, traditional Chinese medicine (TCM) syndrome scores, Hamilton depression (HAMD) scale scores, self-rating depression scale (SDS) scores, self-Rating Anxiety Scale (SAS) scores, athens insomnia scale (AIS) scores, serological indicators, blood pressure, and adverse events. RevMan 5.3 Software was used for data analyses. GRADE system was used to assess the level of evidence. RESULTS: Sixteen eligible studies with 1594 subjects were identified. Five studies showed EXD was contradictory results according to Kupperman index of menopausal syndrome compared with hormone. One study showed EXD significantly improved total hot flush scores, total MRS scores and total MENQOL scores compared with placebo (P < 0.05). Meta-analysis of 10 EXD monotherapy or 2 paratherapy studies showed that both can significantly improve total effective rate compared with hormone (P < 0.05); 3 studies showed that EXD plus hormone significantly reduces the TCM syndrome scores, HAMD scale scores, SDS scores and SAS scores compared with hormone (P < 0.05). One study showed a significant effect of EXD for reducing AIS scores compared with hormone (P < 0.05); 7 studies showed contradictory effects for improving serological indicators compared with hormone. Two studies reported adverse effects, whereas the other studies did not mention. The quality of the evidence of primary outcomes was moderate to high according to the GRADE profiler. CONCLUSIONS: The present findings do not allow an assessment of the evidence because the low-quality studies included cannot be reproduced. However, we identified an area, which is worthy of further research. Rigorous RCTs are still needed in the future.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Lou XT, Shi YH, et al. Erxian decoction, a Chinese herbal formula, for menopausal syndrome: An updated systematic review. J Ethnopharmacol. 2019. PMID: 30658181. doi:10.1016/j.jep.2019.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。